Received Nov 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 4 | 946914 | IM / LA |
No adverse events noted
DM2, Anemia, Constipation, End Stage Renal Disease, HTN, Fluid overload, Hyperlipidemia, Hypokalemia, malignant neoplasm of prostate
DM2, End stage renal disease, HTN, Anemia
yes
NKA
N/A